Jan 26, 2017 7:00am EST Matinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017
Jan 23, 2017 7:05am EST Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
Jan 19, 2017 7:05am EST Matinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants
Dec 08, 2016 7:05am EST Matinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF
Dec 05, 2016 7:05am EST Matinas BioPharma Commences Dosing in Phase 1 Study of Orally Administered Aminoglycoside Antibiotic MAT2501
Nov 21, 2016 7:05am EST Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis
Nov 15, 2016 7:05am EST Matinas BioPharma Reports 2016 Third Quarter Financial Results and Provides Corporate Update
Nov 03, 2016 7:35am EDT Matinas BioPharma Researchers Among Rutgers University Recipients of 2016 Edison Patent Awards
